| Stage | BIO | % of rev | LAZ | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $651M | 100.00% | $836M | 100.00% | LAZ ×1.28 |
| Gross profit | $346M | 53.12% | $267M | 31.97% | BIO +21.1pp |
| Operating income | $73M | 11.15% | $55M | 6.55% | BIO +4.6pp |
| Pre-tax income | $542M | 83.27% | $55M | 6.55% | BIO +76.7pp |
| Net income | $371M | 57.05% | $30M | 3.55% | BIO +53.5pp |
| Stage | BIO | LAZ | Gap · A − B |
|---|---|---|---|
| Revenue | $651M100.00% | $836M100.00% | LAZ ×1.28 |
| Gross profit | 53.12%$346M | 31.97%$267M | BIO +21.1pp |
| Operating income | 11.15%$73M | 6.55%$55M | BIO +4.6pp |
| Pre-tax income | 83.27%$542M | 6.55%$55M | BIO +76.7pp |
| Net income |
| 57.05%$371M |
| 3.55%$30M |
| BIO +53.5pp |
No shared counterparties.